The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Expires: July 31, 2015
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
CYTOKINETICS INC COM 23282W605 47,105,547 714,695 SH SOLE 714,695 0 0
Eikon Therapeutics, Inc. COM 282564103 15,627,203 1,943,682 SH SOLE 1,943,682 0 0
Pharvaris N.V. COM N69605108 151,576,589 4,778,581 SH SOLE 4,778,581 0 0
Relay Therapeutics, Inc. COM 75943R102 22,562,500 1,250,000 SH SOLE 1,250,000 0 0
VERACYTE, INC. COM 92337F107 9,208,000 200,000 SH SOLE 200,000 0 0
Xenon Pharmaceuticals Inc. COM 98420N105 5,950,400 160,000 SH SOLE 160,000 0 0